Moderna (MRNA) jumped 177% on Wednesday, and the strangest part is how little news it took. A $200 million estimate change moved $30 billion on the stock market.
Moderna became famous for its COVID vaccine five years ago, and its stock price is now at its highest since mid-2024. So, investors wasted no time taking profits after such a massive rally.
But can the stock price climb further? Or will the rally stop here?
What Actually Made Moderna Jump 130%?
The drug did not do it alone. Leerink's revised estimate raised its 2032 sales estimate by roughly $200 million. Yet, the stock moved 150 times that amount in a market already at record highs.
The 150x Gap: BeInCrypto Five loaded conditions did the rest. Moderna had collapsed 95% from $484 to $22. The recovery was already running, up 357% in 2026 on a flu approval before the cancer news.
Moderna's Collapse Came First: BeInCrypto The price sat above all six moving averages while analysts refused to believe with a $52.95 average target under the current price.
Bearish MRNA Analysts: TipRanks And short sellers, traders who borrow shares and sell them betting on a fall, held 13.37% short interest in the freely traded shares, losing $4.8 billion when the readout forced them to buy back.
$MRNA Moderna carried a 13.5% short interest into today, among the most-shorted large caps. One trial readout later, shorts are sitting on roughly .8 billion in mark-to-market losses, near 0 a share. That is what a real binary catalyst does to a crowded book.
— Alpha🐺 (@Market_Alpha_) August 19, 2026
The Five Conditions Behind the Moderna Rally: BeInCrypto Moderna Stock Price Prediction: What Wall Street Giants Think
The Moderna move is one of those rare biotech events where the fundamental story genuinely changed overnight. The stock still overshot the immediate fundamentals, and today’s pullback is already showing that.
Ignore the old consensus target of roughly $50. Most of those targets were published before the Phase 3 result and are effectively obsolete.
The post-announcement calls are much more useful.
Bank of America upgraded Moderna from Underperform to Neutral and increased its price target enormously, from $40 to $170. BofA described the result as a watershed event because it gives Moderna a credible route away from dependence on infectious-disease vaccines.Morgan Stanley raised its target from $39 to $89, while keeping Equal Weight. Morgan Stanley now sees much greater value in Moderna's scalable mRNA platform, but remains much more conservative on share price.
Brookline Capital: sets a target around $135, with a Buy rating.
William Blair upgraded Moderna from Market Perform to Outperform, arguing that the Phase 3 result puts Moderna and Merck in position to seek regulatory approval and meaningfully changes Moderna's diversification prospects.
So the fresh Street debate has suddenly become something like:
| View | Approx. valuation |
| Morgan Stanley / conservative | $89 |
| Brookline / middle | $135 |
| BofA / bullish | $170 |
| Yesterday's close | $174.38 |
| Current price | ~$140 |
That shows something important – even BofA's extremely aggressive $170 target was below yesterday's closing price.
How Long Will the Moderna Stock Rally Last?
There are really two rallies. The short-squeeze/momentum rally probably peaked yesterday. Today's roughly 20% drop is consistent with that. Once shorts have covered and momentum traders start taking profits, that mechanical buying disappears.
The fundamental revaluation could last much longer. The next major event will likely be publication of the detailed Phase 3 numbers.
So far Moderna and Merck have announced that the endpoints were achieved, without releasing the actual hazard ratios and detailed clinical data.
Analysts still want to see magnitude of benefit, overall-survival trends, safety details and manufacturing economics.
Those detailed results are expected around the ESMO Congress in Madrid, October 23-27. That creates a natural trading window.
Between now and October, Moderna stock is likely to remain extremely volatile, with investors continuously repricing what the full data might show.
If the detailed results are excellent, another leg upward is possible. If they're statistically positive but clinically less spectacular than investors currently imagine, the stock could fall substantially.
Based on what the market shows today, most analysts put Moderna's reasonable near-to-medium-term fundamental range around $120-$150.
Read the Original story 5 Reasons Why Moderna Stock Jumped 170% and How Far It Can Go by Ananda Banerjee at beincrypto.com